{"id":56976,"date":"2026-02-12T21:20:03","date_gmt":"2026-02-12T13:20:03","guid":{"rendered":"https:\/\/flcube.com\/?p=56976"},"modified":"2026-02-12T21:20:06","modified_gmt":"2026-02-12T13:20:06","slug":"guangji-pharma-to-raise-87-million-via-private-placement-to-controlling-shareholder","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56976","title":{"rendered":"Guangji Pharma to Raise $87 Million via Private Placement to Controlling Shareholder"},"content":{"rendered":"\n

Hubei Guangji Pharmaceutical Co., Ltd.<\/strong> (SHE:\u202f000952<\/a><\/strong>) announced plans for a private placement<\/strong> of up to 94.9 million A-shares<\/strong> to its controlling shareholder Yangtze River Industry Group Co., Ltd.<\/strong>, raising up to RMB\u202f600 million (USD\u202f87 million)<\/strong>. The vitamin preparation specialist<\/strong> will use the controlling shareholder cash injection<\/strong> to strengthen its balance sheet<\/strong> and support R&D and production expansion<\/strong> in the competitive Chinese pharmaceutical market<\/strong>.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Issuer<\/strong><\/td>Hubei Guangji Pharmaceutical Co., Ltd. (SHE:\u202f000952)<\/td><\/tr>
Subscriber<\/strong><\/td>Yangtze River Industry Group Co., Ltd. (controlling shareholder)<\/td><\/tr>
Transaction Type<\/strong><\/td>Private placement (A-shares)<\/td><\/tr>
Shares Issued<\/strong><\/td>Up to 94,936,708 shares<\/td><\/tr>
Total Proceeds<\/strong><\/td>RMB\u202f600 million (USD\u202f87 million)<\/strong> maximum<\/td><\/tr>
Subscription Price<\/strong><\/td>RMB\u202f6.32 (USD\u202f0.91)<\/strong> per share<\/td><\/tr>
Pricing Basis<\/strong><\/td>\u226580% of 20-day average trading price prior to pricing reference date<\/td><\/tr>
Payment Method<\/strong><\/td>Full cash subscription<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Shareholding Structure<\/h2>\n\n\n\n
Shareholder<\/th>Pre-Issuance Holdings<\/th>Ownership %<\/th>Post-Issuance Impact<\/th><\/tr><\/thead>
Yangtze River Industry Group<\/strong><\/td>87,592,065 shares<\/td>25.26%<\/strong><\/td>Increased control; potential dilution mitigation<\/td><\/tr>
Other Shareholders<\/strong><\/td>258,408,935 shares<\/td>74.74%<\/td>Minor dilution from placement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Use of Proceeds<\/h2>\n\n\n\n
Priority<\/th>Application<\/th>Strategic Value<\/th><\/tr><\/thead>
R&D Expansion<\/strong><\/td>Vitamin formulation innovation; new therapeutic indications<\/td>Product pipeline diversification beyond commoditized vitamins<\/td><\/tr>
Manufacturing Scale<\/strong><\/td>Production capacity enhancement; quality system upgrades<\/td>Cost competitiveness; regulatory compliance (GMP)<\/td><\/tr>
Working Capital<\/strong><\/td>Operational liquidity; raw material procurement<\/td>Supply chain stability; pricing power in procurement<\/td><\/tr>
Debt Reduction<\/strong><\/td>Balance sheet strengthening<\/td>Improved credit profile; reduced interest expense<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Industry Position<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
Vitamin Market Dynamics<\/strong><\/td>Commoditized, price-sensitive market<\/strong>; oversupply pressure<\/strong> in China; differentiation through formulation innovation<\/strong> critical<\/td><\/tr>
Controlling Shareholder Support<\/strong><\/td>Yangtze River Industry Group cash injection<\/strong> signals long-term commitment<\/strong>; avoids external dilution<\/strong> and market volatility<\/strong><\/td><\/tr>
Private Placement Advantage<\/strong><\/td>Expedited execution<\/strong> vs. public offering; lower transaction costs<\/strong>; targeted strategic investment<\/strong><\/td><\/tr>
SME Pharma Financing Trend<\/strong><\/td>Listed Chinese pharmaceutical companies<\/strong> increasingly rely on controlling shareholder placements<\/strong> amid tightened IPO and refinancing regulations<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Guangji Pharmaceutical’s private placement completion, use of proceeds execution, and vitamin preparation market competitiveness. Actual results may differ due to shareholder approval requirements, pricing volatility affecting placement terms, and vitamin market demand fluctuations.-Fineline Info & Tech<\/a><\/p>\n\n\n\n